RT Journal Article
SR Electronic
T1 Plasma Hydrogen Sulfide Production Capacity is Positively Associated with Post-Operative Survival in Patients Undergoing Surgical Revascularization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.16.21251804
DO 10.1101/2021.02.16.21251804
A1 Longchamp, Alban
A1 MacArthur, Michael R.
A1 Trocha, Kaspar
A1 Ganahl, Janine
A1 Mann, Charlotte G.
A1 Kip, Peter
A1 King, William W.
A1 Sharma, Gaurav
A1 Tao, Ming
A1 Mitchell, Sarah J.
A1 Ditrói, Tamás
A1 Nagy, Péter
A1 Ozaki, C. Keith
A1 Hine, Christopher
A1 Mitchell, James R.
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.16.21251804.abstract
AB Objective Hydrogen sulfide (H2S) is a gaseous signaling molecule and redox factor important for cardiovascular function. Deficiencies in its production or bioavailability are implicated in atherosclerotic disease. However, it is unknown if circulating H2S levels differ between vasculopaths and healthy individuals, and if so, whether H2S measurements can be used to predict surgical outcomes. Here, we examine: 1) Plasma H2S levels in patients undergoing vascular surgery and compare these to healthy controls, and 2) Associations between H2S levels and mortality in surgical revascularization patients.Approach & Results Patients undergoing carotid endarterectomy, open lower extremity revascularization or leg amputation were enrolled. Peripheral blood was also collected from a matched cohort of 20 patients without peripheral or coronary artery disease. Plasma H2S production capacity and sulfide concentration were measured using the lead acetate and monobromobimane methods, respectively. Plasma H2S production capacity and plasma sulfide concentrations were reduced in patients with PAD (p<0.001, p=0.013 respectively). Patients that underwent surgical revascularization were divided into high versus low H2S production capacity groups by median split. Patients in the low H2S production group had increased probability of mortality (p=0.003). This association was robust to correction for potentially confounding variables using Cox proportional hazard models.Conclusions Circulating H2S levels were lower in patients with atherosclerotic disease. Patients undergoing surgical revascularization with lower H2S production capacity, but not sulfide concentrations, had increased probability of mortality within 36 months post-surgery. This work provides insight on the role H2S plays as a diagnostic and potential therapeutic for cardiovascular disease.HIGHLIGHTSVascular disease patients have higher plasma hydrogen sulfide levels than controls without vascular disease as measured by two distinct methods, the lead acetate hydrogen sulfide release method and the HPLC-based monobromobimane method.Only the lead acetate hydrogen sulfide release method robustly predicts survival after vascular surgery intervention over 35 months of follow up.The lead acetate release method measures non-enzymatic hydrogen sulfide release from plasma which requires iron and is catalyzed by vitamin B6.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Swiss National Science Foundation (PZ00P3-185927) to A.L. The National Institutes of Health (R01HL148352) to C.H. P.N. acknowledges financial support from the Hungarian Thematic Excellence Program TKP2020-NKA-26, KH_126766, K_129286 from the Hungarian National Research, Development and Innovation OfficeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was obtained from the Partners Human Research Committee institutional review board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be provided to qualified researchers upon requestCARS2Cysteinyl t-RNA synthetaseCBSCystathionine-beta-synthaseCEACarotid endarterectomyCGLCystathionine-gamma-lyaseCLICritical limb ischemiaH2SHydrogen sulfideMIMyocardial infarctionMBBMonobromobimanePADPeripheral arterial diseasePLPPyridoxal-5-phosphate